Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.

doi:10.1038/mp.2011.38

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.

Molecular psychiatry - 1 Jun 2011

Bigos K L, Bies R R, Pollock B G, Lowy J J, Zhang F, Weinberger D R

Abstract excerpt

The antipsychotic drug, olanzapine, one of the most widely used drugs in clinical medicine, has a high rate of discontinuation due to inefficacy and/or adverse effects. We identified a single nucleotide polymorphism in the drug metabolizing enzyme, cytochrome P450 3A43 (CYP3A43; rs472660), that highly significantly predicted olanzapine clearance in the Clinical Antipsychotic Trials of Intervention Effectiveness...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzodiazepines

Share to Cytochrome P-450 CYP3A

Share to Lipid Metabolism

Share to Models, Chemical

Share to Olanzapine

Share to Psychiatric Status Rating Scales

Share to Weight Gain

Source

Open in PubMed Open full text

Identifiers

PMID: 21519338
DOI: 10.1038/mp.2011.38
PMCID: PMC3100476

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.PMID 21519338Read ↗

No influence of CYP3A43 rs472660G> A on steady-state serum olanzapine concentrations in white psychiatric patients.Semantic proximity Read ↗

Genetic variation in CYP3A43 is associated with response to antipsychotic medication.Semantic proximity Read ↗

The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia.Semantic proximity Read ↗

Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.Semantic proximity Read ↗

Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers.Semantic proximity Read ↗

CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients.Semantic proximity Read ↗

CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.Semantic proximity Read ↗

Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants.Semantic proximity Read ↗

Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects.Semantic proximity Read ↗

Effect of Organic Anion Transporting Polypeptide 1B1 on Plasma Concentration Dynamics of Clozapine in Patients with Treatment-Resistant Schizophrenia.Semantic proximity Read ↗

Pharmacogenetics of Olanzapine MetabolismSemantic proximity Read ↗

The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.